BlackRock
IMPL

BlackRock’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

BlackRock’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,635
Closed -$9.73K – 5480
2023
Q3 		$9.73K Buy
22,635
+5,142
+29% +$4.94K ﹤0.01% 5201
2023
Q2 		$22.2K Sell
17,493
-539
-3% -$817 ﹤0.01% 5194
2023
Q1 		$25.2K Buy
18,032
+462
+3% +$1.1K ﹤0.01% 5225
2022
Q4 		$65.9K Sell
17,570
-89,684
-84% -$327K ﹤0.01% 5159
2022
Q3 		$523K Buy
107,254
+9,783
+10% +$74.9K ﹤0.01% 4712
2022
Q2 		$908K Sell
97,471
-248,201
-72% -$1.81M ﹤0.01% 4574
2022
Q1 		$2.2M Sell
345,672
-9,405
-3% -$71.1K ﹤0.01% 4348
2021
Q4 		$3.06M Buy
355,077
+86,347
+32% +$862K ﹤0.01% 4216
2021
Q3 		$3.27M Buy
268,730
+17,667
+7% +$256K ﹤0.01% 4118
2021
Q2 		$2.22M Buy
+251,063
New +$3M ﹤0.01% 4226

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

BlackRock's IMPL Position: Q4 2023 in Review

BlackRock sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 22,635 shares — an estimated $9.73K sold.

BlackRock first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $3.27M in Q3 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • BlackRock reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 22,635 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $9.73K.
  • BlackRock first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • BlackRock's Impel Pharmaceuticals Inc. Common Stock position peaked at $3.27M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.